zalunfiban

DRUG2 trials

Sponsors

Celecor Therapeutics Inc., CeleCor Therapeutics

Conditions

ST-elevation Myocardial Infarction (STEMI)Subjects with documented STEMIin whom the total duration of symptoms to diagnostic ECG is anticipated to be within 4 hours.presenting with persistent ischemic chest pain (>10 minutes) and new ≥2 mm ST-segment elevation in 2 adjacent ECG leads

Phase 3

A Phase 3 Study of Zalunfiban in Subjects With ST-elevation MI

Active, not recruitingNCT04825743

CeleCor TherapeuticsST-elevation Myocardial Infarction (STEMI)

Start: 2021-04-24End: 2026-05-13Updated: 2025-10-23

A Phase 3 prospective, blinded, randomized, placebo controlled, international multicenter study to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in subjects with ST-elevation myocardial infarction in the pre-hospital setting

Active, not recruitingCTIS2023-508485-15-00

Celecor Therapeutics Inc.in whom the total duration of symptoms to diagnostic ECG is anticipated to be within 4 hours., presenting with persistent ischemic chest pain (>10 minutes) and new ≥2 mm ST-segment elevation in 2 adjacent ECG leads, Subjects with documented STEMI

Start: 2021-04-22Target: 2381Updated: 2025-12-15

Related Papers

Efficacy and Safety of Zalunfiban by Creatinine Clearance Among Patients with ST-Elevation Myocardial Infarction: Analysis from the CELEBRATE Trial.

2026-09-11

Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction.

2025-11-102 citations

Prehospital treatment with zalunfiban (RUC-4) in patients with ST- elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of the CELEBRATE trial.

2022-12-3115 citations